Sun Pharma's specialty product Ilumetri included in China's national reimbursement drug list

13 Dec 2023 Evaluate

Sun Pharmaceutical Industries’ specialty product Ilumetri has been included in category B of China's national reimbursement drug list. Ilumetri is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The inclusion of Ilumetri (Tildrakizumab) in China's national reimbursement drug list will be officially implemented from January 1, 2024. 

In June 2019, Sun Pharma had out-licensed Tildrakizumab to a subsidiary of China Medical System Holdings (CMS), for the Greater China market. Ilumetri was approved for marketing in China in May 2023. 

Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

Sun Pharma Inds. Share Price

1837.30 -16.85 (-0.91%)
08-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1837.30
Dr. Reddys Lab 1370.60
Cipla 1495.05
Lupin 2252.40
Zydus Lifesciences 981.55
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.